# NAVEC Investment Management

> NAVEC Investment Management is a VC fund backing Biotechnology and Therapeutics. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Jun 2026
- Lead investor: 0%
- Last updated: Aug 2026

NAVEC Investment Management is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Therapeutics | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 4 | 80% |
| Seed | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Epitome Therapeutics | Epitome Therapeutics is an early-stage biotechnology company developing CADENCE, a next-generation epigenome editing platform for precise, durable, and context-dependent control of gene expression without altering the underlying DNA sequence, with the aim of establishing a new therapeutic modality for diseases driven by dysregulated gene activity. | $2.3M | Pre-Seed | Jun 30, 2026 |  |
| Graph Therapeutics | Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of people are leftwithout adequate treatment options - and AI trained with complex disease data can solve this. | $5M | Seed | Jun 22, 2026 |  |
| Theorema | Theorema.ai is an AI-powered startup that focuses on autonomous R&D agents for science-intensive industries, including innovative materials, biotech, pharmaceuticals, and chemicals. | $3.3M | Pre-Seed | Mar 27, 2026 |  |
| Metri Bio | Metri Bio is a healthcare company that focused on endometrial diseases to improve lives of people. | $5M | Pre-Seed | Dec 02, 2025 |  |
| Graph Therapeutics | Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of people are leftwithout adequate treatment options - and AI trained with complex disease data can solve this. | $3.1M | Pre-Seed | Jan 09, 2025 |  |

5 of 5 investments shown.

## Co-investors
- [Merantix Capital](https://shizune.co/investors/profile/merantix) — VC Fund, 2 deals together
- [SquareOne Venture Capital](https://shizune.co/investors/profile/squarone-vc) — VC Fund, 2 deals together
- [Amino Collective](https://shizune.co/investors/profile/amino-collective) — VC Fund, 1 deal together
- [Caesar Ventures](https://shizune.co/investors/profile/caesar-ventures-llc) — VC Fund, 1 deal together
- [Credo Ventures](https://shizune.co/investors/profile/credo-ventures) — VC Fund, 1 deal together
- [Daphni](https://shizune.co/investors/profile/daphni) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

## FAQ

### What does NAVEC Investment Management invest in?

NAVEC Investment Management invests primarily in Biotechnology and Therapeutics startups, most often at Pre-Seed and Seed stage. Most of the 5 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did NAVEC Investment Management last invest?

The most recent investment recorded for NAVEC Investment Management closed in Jun 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co